Marksans Pharma Ltd (BOM:524404)

Q4 2026 Marksans Pharma Ltd Earnings Call Transcript

May 27, 2026 / 11:00 AM GMT

Release Date Price: ₹248.9 (-2.18%)

Transcript

Key Points

Positve

Marksans Pharma Ltd (BOM:524404) achieved a significant milestone by crossing 3,000 crores in net income for the first time, delivering its highest ever profitability.
The company expanded its international footprint by entering new markets such as Germany, Canada, and Ireland, and strengthened its presence in Australia.
Revenue from North America, the largest and fastest-growing market, reached 1,533 crores, reflecting a growth of 24% year-on-year.
Gross margin improved to 56.7%, while EBITDA margin expanded to 20.4%, with Q4 margins particularly strong at 22.8%.
Marksans Pharma Ltd (BOM:524404) remains debt-free with a cash balance of approximately 990 crores, providing substantial flexibility for future growth investments.

Negative

The company faces near-term external headwinds, including raw material cost inflation due to geopolitical and supply chain disruptions.
Pricing pressure in the UK market impacted revenues in the early part of FY26, although there was recovery in the second half.
There is uncertainty regarding the impact of raw material cost inflation on margins, with potential for increased costs if inventory runs out.
The working capital cycle has increased due to strategic decisions to maintain higher inventory levels amid market uncertainties.
Logistics costs remain volatile, with potential impacts on margins if geopolitical tensions persist.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

MARK.NS - Marksans Pharma Ltd
Q4 2026 Marksans Pharma Ltd Earnings Call
May 27, 2026 / 11:00AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, good day and welcome to the Marksons Pharma Limited Q4 FY26 Earnings Conference Call hosted by Dam Capital.

As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes.

Should you need assistance during this conference, please signal an operator by pressing then 0 on your touchstone phone.

Please note that this conference is being recorded.

I now hand the conference over to Mr. Nitin Agarwal from DAM Capital.

Thank you, and over to you, sir.

--------------------------------------------------------------------------------
Unidentified_2 [2]
----------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.